-+ 0.00%
-+ 0.00%
-+ 0.00%

Rein Therapeutics enrolls 8 patients in Phase 2 IPF trial for LTI-03

PUBT·04/29/2026 12:03:31
Listen to the news
Rein Therapeutics enrolls 8 patients in Phase 2 IPF trial for LTI-03
  • Rein Therapeutics reported accelerated enrollment in Phase 2 RENEW study of LTI-03 for idiopathic pulmonary fibrosis.
  • Study enrolled 8 patients to date, with 2 more expected this week.
  • Enrollment started in March 2026, with additional patients being added on a regular basis.
  • Trial sites are active in United States, Australia, Poland, with United Kingdom and Germany expected to open soon.
  • No clinical results have been presented yet, with update focused on enrollment progress and site expansion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604290800PRIMZONEFULLFEED9708567) on April 29, 2026, and is solely responsible for the information contained therein.